Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | TPMT | P51580 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | G6PD | P11413 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CCR6 | P51684 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29421972 | 1.00 | TDP1 (0.54) | TDP1PTPN1MAPTCYP3A4TPMT | |
| SCHEMBL28272590 | 0.83 | TDP1 (0.52) | TDP1PTPN1MAPTCYP3A4TPMT | |
| SCHEMBL27694686 | 0.83 | TDP1 (0.52) | TDP1PTPN1MAPTCYP3A4TPMT | |
| SCHEMBL29727382 | 0.83 | TDP1 (0.58) | TDP1PTPN1MAPTCYP3A4TPMT | |
| SCHEMBL1961832 | 0.83 | TDP1 (0.58) | TDP1PTPN1MAPTCYP3A4TPMT | |
| SCHEMBL28274926 | 0.83 | TDP1 (0.52) | TDP1PTPN1MAPTCYP3A4ALDH1A1 | |
| SCHEMBL8249793 | 0.83 | TDP1 (0.52) | TDP1PTPN1MAPTCYP3A4TPMT | |
| SCHEMBL7554717 | 0.82 | HTT (0.56) | TDP1MAPTTPMTALDH1A1KDM4E | |
| SCHEMBL8254929 | 0.81 | ACHE (0.46) | TDP1PTPN1MAPTCYP3A4ALDH1A1 | |
| SCHEMBL31090180 | 0.78 | PTPN1 (0.53) | TDP1PTPN1MAPTCYP3A4TPMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1915333-B1 | PROCESS FOR THE PREPARATION OF UBIHYDROQUINONES AND UBIQUINONES | DSM IP ASSETS BV (NL) | 2015-06-03 | — | — | EP | disclosed |
| CN-101243031-B | Process for preparing ubiquinones and ubiquinones | DSM IP ASSETS BV | 2012-05-09 | — | — | CN | disclosed |
| US-7601877-B2 | Condensation of a prenol or isoprenol with a hydroquinone or derivative in the presence of 0.005-1.0 mol percent of a Bronsted or Lewis acid catalyst selected from a bismuth, indium or Group 3 chloride, a heteropolyacid, and an NH- or a CH-acidic compound, oxidizing the ubihydroquinone; improved kinetics | DSM IP ASSETS B.V. (NL) | 2009-10-13 | — | — | US | disclosed |
| US-20080275275-A1 | Process for the Preparation of Ubihydroquinones and Ubiquinones | DSM IPASSETS B.V. (NL) | 2008-11-06 | — | — | US | disclosed |
| EP-1915333-A1 | PROCESS FOR THE PREPARATION OF UBIHYDROQUINONES AND UBIQUINONES | DSMIP Assets B.V. (NL) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007017168-A1 | PROCESS FOR THE PREPARATION OF UBIHYDROQUINONES AND UBIQUINONES | DSM IP ASSETS B.V. (NL) | 2007-02-15 | — | — | WO | disclosed |
| US-4992469-A | Prevention of cardiovascular disorder; phospholipase inhibitor | EISAI CO., LTD. (JP) | 1991-02-12 | — | — | US | disclosed |
| EP-0163317-B1 | QUINONE DERIVATIVES, METHOD AND USE OF PREPARING SAME, AND PHARMACEUTICAL COMPOSITION | Eisai Co., Ltd. (JP) | 1988-08-24 | — | — | EP | disclosed |
| EP-0163317-A1 | Quinone derivatives, method and use of preparing same, and pharmaceutical composition | Eisai Co., Ltd. (JP) | 1985-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275275-A1 | Process for the Preparation of Ubihydroquinones and Ubiquinones | UBE2D3, UBE2L3, UBE2I | TDP1 4456/4885PTPN1 4654/4885MAPT 2939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.